Sign In
Last checked at 
20 Oct 2021 16:27
IXICO plc
("IXICO" or the "Company")
Contract update
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has been notified by a client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data.
The client will therefore end its trial while it undertakes additional preclinical studies. Contracted revenues for this trial represented £3.3m of the Company's order book as at 30 September 2021, of which the Company had expected to deliver £0.8m revenues in the financial year to 30 September 2022.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)
For further information please contact:
IXICO plc | +44 (0) 20 3763 7498 |
| ||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
|
| ||
|
|
| ||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0) 20 7397 8900 |
| ||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
|
| |||
Walbrook PR Ltd | Tel: 020 7933 8780 or IXICO@walbrookpr.com | |||
Paul McManus / Lianne Applegarth / |
| |||
Alice Woodings |
| |||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
Follow the stocks
